UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
PURSUANT TO SECTION 13 OR 15(d)
OF THE SECURITIES EXCHANGE ACT OF 1934
Date of Report (Date of Earliest Event Reported): July 14, 2008
Pharmasset, Inc.
(Exact Name of Issuer as Specified in Charter)
| Delaware | 001-33428 | 98-0406340 | ||
| (State or Other Jurisdiction of Incorporation or Organization) |
(Commission File Number) | (I.R.S. Employer Identification Number) |
| 303-A College Road East Princeton, New Jersey |
08540 | |
| (Address of Principal Executive Offices) | (Zip Code) |
(609) 613-4100
(Registrant’s Telephone Number, Including Area Code)
(Former Name or Former Address, if Changed Since Last Report)
Check the appropriate box below if the Form 8-K is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
| ¨ | Written communications pursuant to Rule 425 under the Securities Act |
| ¨ | Soliciting material pursuant to Rule 14a-12 under the Exchange Act |
| ¨ | Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act |
| ¨ | Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act |
| Item 1.01. | Entry Into a Material Definitive Agreement. |
On July 14, 2008, Pharmasset, Inc. (the “Company”) entered into a placement agency agreement (the “Placement Agency Agreement”) with Morgan Stanley & Co. Incorporated (“Morgan Stanley”) on its own behalf and on behalf of each of the other placement agents named in Schedule II thereto (collectively, with Morgan Stanley, the “Placement Agents”), relating to the proposed offering to a group of institutional investors of 1,450,000 shares (the “Shares”) of the Company’s common stock, par value $0.001 per Share (the “Offering”). A copy of the Placement Agency Agreement is filed as Exhibit 10.1 to this Current Report on Form 8-K and incorporated herein by reference. The description of the material terms of the Placement Agency Agreement is qualified in its entirety by reference to such exhibit.
In connection with the Offering, on July 14, 2008, the Company also entered into an Investor Purchase Agreement with each investor purchasing Shares in the Offering. The investors have agreed to purchase the Shares for a price of $17.85 per Share. A copy of the form of Investor Purchase Agreement is filed as Exhibit 10.2 to this Current Report on Form 8-K and incorporated herein by reference. The description of the material terms of the Investor Purchase Agreement is qualified in its entirety by reference to such exhibit.
The closing of the Offering is expected to take place on or about July 21, 2008, subject to the satisfaction of customary closing conditions.
The Shares are being offered and sold pursuant to a prospectus dated June 26, 2008, a prospectus supplement dated July 14, 2008, a term sheet distributed to investors on July 14, 2008 (and filed separately as a free writing prospectus pursuant to the requirements of Rule 433 of the Securities Act of 1933, as amended) and the Company’s shelf registration statement on Form S-3 (Registration No. 333-151749), which was declared effective on June 26, 2008.
The legal opinion and consent of Pepper Hamilton LLP relating to the Shares is filed as Exhibit 5.1 to this Current Report on Form 8-K and is incorporated herein by reference.
The net proceeds from the sale of the Shares, after deducting the fees of the Placement Agents and other offering expenses, will be approximately $24.18 million. The Placement Agents will receive an aggregate fee of $1,552,950, which represents 6% of the aggregate purchase price for the Shares. The Company’s press release dated July 15, 2008, announcing the agreement to sell the Shares is filed as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated herein by reference.
| Item 9.01. | Financial Statements and Exhibits. |
| (d) | The following exhibits are furnished with this report on Form 8-K: | |
| 5.1 | Opinion of Pepper Hamilton LLP | |
| 10.1 | Placement Agency Agreement dated July 14, 2008 by and among Pharmasset, Inc. and Morgan Stanley & Co. Incorporated on its own behalf and on behalf of each of the other placement agents named in Schedule II thereto | |
| 10.2 | Form of Investor Purchase Agreement | |
| 23.1 | Consent of Pepper Hamilton LLP (reference is made to Exhibit 5.1 hereto) | |
| 99.1 | Press Release of Pharmasset, Inc. dated July 15, 2008 | |
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
| Pharmasset, Inc. | ||||||||
| Date: July 15, 2008 | By: | /s/ Kurt Leutzinger | ||||||
| Kurt Leutzinger | ||||||||
| Chief Financial Officer | ||||||||
EXHIBIT INDEX
| Exhibit |
Exhibit | |
| 5.1 | Opinion of Pepper Hamilton LLP | |
| 10.1 | Placement Agency Agreement dated July 14, 2008 by and among Pharmasset, Inc. and Morgan Stanley & Co. Incorporated on its own behalf and on behalf of each of the other placement agents named in Schedule II thereto | |
| 10.2 | Form of Investor Purchase Agreement | |
| 23.1 | Consent of Pepper Hamilton LLP (reference is made to Exhibit 5.1 hereto) | |
| 99.1 | Press Release of Pharmasset, Inc. dated July 15, 2008 | |